- All
- Anesthesiology
- Anti-infectives and immunology
- Biologicals
- Blood disorders
- Cardiovascular
- CNS
- Diabetes
- Endocrinology/Sexual health
- Gastrointestinal Diseases
- General modelling
- Lung Diseases
- Methods
- Oncology
- Paediatrics
- Pain
- Peripheral Nervous System
- Safety pharmacology
Bosch R., Petrone M., Arends R., Vicini P., Sijbrands E.J. G., Hoefman S., Snelder N. Characterisation of cotadutide’s dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. British Journal of Pharmacology, 2024 [Link to publication].
Sepp A., Muliaditan M. Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies. Mabs, 2024 [Link to publication].
Noort van M., Ruppert M., DeJongh J., Marostica E., Bosch R., Mešić E., Snelder N. Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development. CPT: Pharmacometrics & Systems Pharmacology 2024 [Link to publication].
Wu Y., Allegaert K., Flint R.B., GouloozeS.C., Välitalo P.A.J., Hoog de M., Mulla H., Sherwin C.M.T., Simons S.H.P., Krekels E.H.J., Knibbe C.A.J., Völler S. When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers? Pharmaceutical Research 2024 [Link to publication].
Noort van M., Ruppert M. Two new user-friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scales. CPT: Pharmacometrics & Systems Pharmacology, 2024 [Link to publication].
Bosch R, Sijbrands E.J.G, Snelder N. Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model. CPT: Pharmacometrics & Systems Pharmacology, 2024 [Link to publication].
Admiraal M.M., Velseboer D.C., Tjabbes H., Vis P., Peeters-Scholte C., Horn J. Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics. Frontiers in Neurology 2023. [Link to publication ].
Goulooze S.C, Vis P., Krekels E.H.J., Knibbe C.A.J. Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses. Expert Review of Clinical Pharmacology 2023 [Link to publication].
Eissing T., Goulooze S.C., Berg van der P., Noort van M., Ruppert M., Snelder N., Garmann D., Lippert J., Heinig R., Brinker M., Heerspink H.J.L. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, Obesity and Metabolism 2023 [Link to publication].
Noort van M., Ruppert M., Goulooze S.C., Berg van den P., Snelder N., Heerspink H.J., Garmann D., Lippert J., Heinig R., Brinker M., Eissing T. From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies. PAGE 2023 [Link to publication]
Richard Hooijmaijers R., Parasrampuria R., Marostica E., Ferron-Brady G., Post T.M., Visser S.A.G. Building an adaptive dose simulation framework to aid dose and schedule selection. CPT: Pharmacometirics & Systems Pharmacology, 2023. [Link to publication].
Collins J., Noort van M., Rathi C., Post T.M., Struemper H., Jewell R.C., FerronBrady G. Longitudinal Efficacy and Safety Modeling and Simulation Framework to Aid Dose Selection of Belantamab Mafodotin for Patients with Multiple Myelo. CPT Pharmacometrics Syst. Pharmacol. 2023 [Link to publication].
Jensen J.T., Reinecke I., Post T.M. , Lukkari-Lax E. , Hofmann B.M. Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs. Contraception, 2023. [Link to publication].
Fu Y., Snelder N., Guo T., Graaf van der P.H., Hasselt J.G.C. Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics, 2023 [Link to publication].
Willmann S., Keller A.K., Meyer M., van der Mey D., Wirsching G., Zhang Y., Drenth H., Keunecke A., Vendel E. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension. Pediatiric Pulmonology, 2022. [Link to publication].